Open AccessP1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA
Author(s) -
Frigault M.,
Sher S.,
Ravikrishnan J.,
Izumi R.,
Ware J.,
Wong H.,
Johnson A.,
StelteLudwig B.,
Byrd J.,
Sampath D.,
Rogers K.,
Woyach J.,
Lapalombella R.,
Hamdy A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847940.03718.3d
Subject(s) - ibrutinib , kinome , venetoclax , lymphoma , cancer research , pharmacodynamics , chronic lymphocytic leukemia , pharmacology , medicine , leukemia , pharmacokinetics , oncology , chemistry , kinase , biochemistry